The Adrenergic System in Pulmonary Arterial Hypertension: Bench to Bedside (2013 Grover Conference Series)
Why the study?
Could antiadrenergic treatment (β-blockers) be effectively and safely employed in patients with right ventricular dysfunction due to moderate-severe pulmonary arterial hypertension?
Structured PICO
Could antiadrenergic treatment (β-blockers) be effectively and safely employed in patients with right ventricular dysfunction due to moderate-severe pulmonary arterial hypertension?
P
Population
Patients with right ventricular dysfunction due to moderate-severe pulmonary arterial hypertension (PAH)
I
Intervention
Antiadrenergic treatment (β-adrenergic receptor blocking agents)
This review provides a theoretical rationale for investigating β-blocker therapy to treat right ventricular dysfunction in patients with pulmonary arterial hypertension, drawing parallels from the historical development of β-blockers for HFrEF.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Theoretical rationale supports investigating β-blockers for PAH right ventricular dysfunction; leaves open clinical efficacy pending prospective trials.
Cite This Study
Bristow et al. (2015) studied this question.